Valuation: Adocia

Market Cap 8.16Cr 9.52Cr 7.63Cr 6.98Cr 13Cr 911.6Cr 13Cr 90Cr 35Cr 457.75Cr 36Cr 35Cr 1.51TCr P/E 2026 *
-761x
P/E 2027 * 6.03x
Enterprise Value 5.17Cr 6.04Cr 4.84Cr 4.43Cr 8.35Cr 578.16Cr 8.44Cr 57Cr 22Cr 290.32Cr 23Cr 22Cr 960.55Cr EV / Sales 2026 *
20.5x
EV / Sales 2027 * 3.16x
Free-Float
96.05%
Yield 2026 *
-
Yield 2027 * -
1 week+0.58%
Current month+5.01%
1 month+11.20%
3 months-16.20%
6 months-40.46%
Current year-34.85%
1 week 4
Extreme 4
4.26
1 month 3.69
Extreme 3.694
4.28
3 years 3
Extreme 2.995
14.84
5 years 2.72
Extreme 2.725
14.84
10 years 2.72
Extreme 2.725
62.21
Manager TitleAgeSince
Chief Executive Officer 55 11/05/2023
Director of Finance/CFO - 23/09/2024
Chief Tech/Sci/R&D Officer - 01/12/2014
Director TitleAgeSince
Director/Board Member 55 19/04/2013
Chairman 80 24/02/2012
Director/Board Member 58 18/06/2013
Change 5-day change 1-year change 3-year change Capi.($)
-2.65%+0.58%-51.63%-62.68% 9.52Cr
-4.31%-2.14%+65.79%+103.90% 7.21TCr
-4.19%+18.35%+52.79%+86.77% 6.59TCr
-3.22%+23.17%+7.38%-5.23% 2.93TCr
-1.42%-3.38%-3.38%+465.34% 2.75TCr
-4.71%+7.67%+47.63%+18.25% 2.67TCr
-1.81%+4.19%+34.52%-17.69% 2.01TCr
+5.36%-1.67%+270.18%+415.10% 1.82TCr
-2.79%+0.48%+12.09%+562.03% 1.64TCr
+0.87%+4.26%+43.93%+150.80% 1.34TCr
Average -1.80%+8.55%+47.93%+171.66% 3.22TCr
Weighted average by Cap. -2.83%+8.78%+55.30%+154.58%

Financials

2026 *2027 *
Net sales 25.22L 29.42L 23.59L 21.57L 40.7L 28Cr 41.13L 2.79Cr 1.09Cr 14Cr 1.1Cr 1.08Cr 47Cr 3.54Cr 4.13Cr 3.31Cr 3.03Cr 5.71Cr 395.52Cr 5.77Cr 39Cr 15Cr 198.61Cr 16Cr 15Cr 657.12Cr
Net income -43.17L -50.37L -40.39L -36.92L -69.68L -48Cr -70.42L -4.78Cr -1.86Cr -24Cr -1.89Cr -1.85Cr -80Cr -4.43Cr -5.17Cr -4.15Cr -3.79Cr -7.15Cr -495.27Cr -7.23Cr -49Cr -19Cr -248.69Cr -19Cr -19Cr -822.84Cr
Net Debt -2.98Cr -3.48Cr -2.79Cr -2.55Cr -4.82Cr -333.44Cr -4.87Cr -33Cr -13Cr -167.43Cr -13Cr -13Cr -553.98Cr 3.02Cr 3.52Cr 2.82Cr 2.58Cr 4.87Cr 337.16Cr 4.92Cr 33Cr 13Cr 169.3Cr 13Cr 13Cr 560.15Cr
Logo Adocia
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2025, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram and BioChaperone Glucagon) and 4 preclinical-stage products (AdoShell® Islets, AdOral® Sema, AdoGel® Sema and BioChaperone® CagriSema).
Employees
-
Date Price Change
25/26/25 4.040 -2.65%
21/26/21 €4.150 +1.17%
20/26/20 €4.102 -2.66%
19/26/19 €4.214 +0.72%
18/26/18 €4.184 -0.85%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.060EUR
Average target price
9.700EUR
Spread / Average Target
+138.92%

Quarterly revenue - Rate of surprise